Physician

John M Wallmark, M.D.

According to 2025 Medicare claims, John Wallmark, M.D. (NPI: 1689755365) practices hematology/oncology in the Frederick-Gaithersburg-Bethesda, MD market, with the plurality of this provider's patient population coming from Montgomery, MD. This provider's primary affiliated billing organization is MARYLAND ONCOLOGY HEMATOLOGY, P.A. (NPI: 1821271032; TIN: 113652573) and primary practice location at 20850-6535.

Wallmark's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 868 traditional Medicare patients, billed 194,041 HCPCS/CPT codes, and received $3,423,334 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,025 prescription claims across 206 beneficiaries totaling $4,711,075 in drug costs, led by Revlimid (Lenalidomide). DME data shows 13 claims. Open Payments data shows 115 records totaling $164,748. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,241,457 to $3,423,334. Similarly, Part D prescription costs have moved sharply higher in recent years, from $974,727 to $4,711,075. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	670	95,749	$1,241,457
2016	1,001	143,393	$1,594,388
2017	2,630	147,165	$1,664,168
2018	1,407	178,508	$2,018,675
2019	712	134,285	$1,746,932
2020	708	161,688	$2,043,579
2021	756	149,508	$2,129,230
2022	785	201,169	$2,788,694
2023	777	201,771	$2,950,284
2024	868	194,041	$3,423,334

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	114	589	$974,727
2016	130	775	$1,604,617
2017	111	622	$1,562,045
2018	126	652	$1,764,884
2019	116	624	$1,989,582
2020	124	663	$2,046,128
2021	135	682	$2,433,504
2022	168	837	$2,832,971
2023	170	860	$3,172,672
2024	206	1,025	$4,711,075

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	47	$3,582
2016	N/R	64	$22,586
2017	N/R	14	$8,093
2018	N/R	104	$12,634
2019	N/R	N/R	N/R
2020	N/R	51	$4,843
2021	N/R	25	$1,675
2022	N/R	45	$1,322
2023	N/R	50	$6,679
2024	N/R	13	$226

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	457	872	$107
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	280	408	$72
82728	Ferritin (blood protein) level	147	369	$13
80053	Blood test, comprehensive group of blood chemicals	451	1,945	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	465	2,168	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	27	756	$664,961
Pomalyst	Pomalidomide	17	476	$413,147
Tagrisso	Osimertinib Mesylate	22	660	$353,324
Verzenio	Abemaciclib	24	672	$351,567
Lorbrena	Lorlatinib	13	390	$274,729

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	13	$226

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	67	$2,630	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	48	$162,118	Merck Sharp & Dohme LLC
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for John M. Wallmark, M.D.?

Tedicare shows public-source Medicare data for John M. Wallmark, M.D. (NPI 1689755365), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does John M. Wallmark, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to John M. Wallmark, M.D.?

John M. Wallmark, M.D. is linked to MARYLAND ONCOLOGY HEMATOLOGY, P.A. (billing NPI 1821271032) in the available physician profile data.

Does John M. Wallmark, M.D. have Open Payments data?

John M. Wallmark, M.D. has 115 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.